



**Press release**

**Synairgen plc**  
(‘Synairgen’ or the ‘Company’)

**Result of AGM**

**Southampton, UK** – 03 June 2019: Synairgen (LSE: SNG), the respiratory drug discovery and development company, is pleased to announce that all resolutions proposed at its Annual General Meeting, held earlier today, were duly passed.

As announced on 18 April 2019, Paul Clegg has retired from the Board as a non-executive director, effective on 3 June 2019 (today).

- Ends -

**For further enquiries, please contact:**

**Synairgen plc**

Richard Marsden, Chief Executive Officer  
John Ward, Finance Director  
Tel: + 44 (0) 23 8051 2800

**finnCap**

Geoff Nash, Max Bullen-Smith (Corporate Finance)  
Alice Lane (ECM)  
Tel: + 44 (0) 20 7220 0500

**Consilium Strategic Communications (Financial Media and Investor Relations)**

Mary-Jane Elliott, Sue Stuart, Olivia Manser  
synairgen@consilium-comms.com  
Tel: +44 (0) 20 3709 5700

**About Synairgen**

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging its scientific and clinical facilities at Southampton General Hospital, the Company uses *in vitro* and *ex vivo* models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development.

Synairgen is currently conducting a two-part Phase II trial evaluating SNG001, the Company’s inhaled interferon beta (IFN-beta) product. The Phase II trial, called SG015, has been designed to assess the safety of SNG001 in COPD patients and its clinical benefit in these patients when they have a cold or flu infection, a major driver of COPD exacerbations.

Core to Synairgen’s business strategy is the realisation of value via licensing transactions. In August 2015 the Company entered into a collaboration with Pharmaxis

to develop an oral LOXL2 inhibitor to reduce fibrosis in patients with idiopathic pulmonary fibrosis (IPF). In December 2017, the collaboration agreement was amended as Pharmaxis took on full responsibility for the programme, with Synairgen receiving a £5 million upfront payment and a share of at least 17% (net of allowable expenses) of any receipts from any onward licensing by Pharmaxis of the LOXL2 inhibitors in fibrotic indications.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see [www.synairgen.com](http://www.synairgen.com)